According to the parties, the “long road to diagnosis” is key issue that affects the health, longevity and well-being for rare disease patients and their families. The Global Commission to End the Diagnostic Odyssey for […]
NICE has also recommended that Eisai’s Lenvima (lenvatinib) should be routinely available. Cometriq, which treats medullary thyroid cancer (MTC) was previously available via the Cancer Drugs Fund, and under the new-look NICE appraisal system, successfully […]
The drug has been approved for patients whose cancer has not progressed following concurrent platinum-based chemotherapy and radiation therapy, and is unresectable─ cannot be removed completely through surgery. It is the only immunotherapy approved for […]
Published in Nature Communications, their study demonstrated the potential application of a technique that uses nanoparticles and near infrared laser treatment to cause cancer cells to lose their multidrug resistance capabilities. Multidrug resistance presents a […]
The drug, which won approval in Europe in August last year, is an oral, once-daily, potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) that works by reducing the supply of blood to […]